{"denoms":[{"counts":[{"groupId":"BG000","value":"40"}],"units":"Participants"}],"groups":[{"description":"Participants received thalidomide in 28-day cycles: 50 mg, for the first 2 weeks, escalated to 100 mg for the next 2 weeks and beginning with Cycle 2, to 200 mg once daily. Elotuzumab, 10 mg/kg, was administered as an intravenous infusion weekly for the first 2 cycles and beginning with Cycle 3, every 2 weeks. Dexamethasone, 40 mg, was administered weekly on those weeks when elotuzumab was not administered. On weeks when elotuzumab was also given, participants received dexamethasone as a split dose of 28 mg, 3 to 24 hours before the elotuzumab infusion, and 8 mg intravenously at least 45 minutes before the infusion. Those patients with suboptimal response, defined as evidence of progressive disease between end of Cycle 2 and end of Cycle 4 or inability to achieve partial response or better by end of Cycle 4, also received cyclophosphamide, 50 mg. Cyclophosphamide could not be added beyond Cycle 5.","id":"BG000","title":"Thalidomide + Elotuzumab + Dexamethasone + Cyclophosphamide"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.47","value":"64.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"Younger than 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"65 years and older to younger than 75 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"75 years and older"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"25"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"40"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"Immunoglobulin (Ig)G"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"IGA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"IGM"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"IGD"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Light chain disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Not reported"}],"paramType":"NUMBER","title":"Myeloma type","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Score 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":"Score 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Score 2"}],"description":"ECOG is a 6-item scale used to assess disease progression, daily functioning, appropriate treatment, and prognosis. Performance status is scored on a scale ranging from 0-5, with (best score) 0=fully active and able to carry on all predisease performance without restriction and (worst score) 5=death.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) performance status","unitOfMeasure":"Participants"}],"populationDescription":"All participants who received thalidomide +elotuzumab + dexamethose (40) and had cyclophosphamide added to the regimen (11)."}